Trial
NCT00522301
Sorafenib in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in at Least the Second Remission
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Memorial Sloan Kettering Cancer Center
Collaborators
National Cancer Institute (NCI); Bayer
Condition
Fallopian Tube Cancer
Intervention
sorafenib tosylate
Why stopped
—
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2016-02-29